dc.contributor.author Dranitsaris, George en_US dc.contributor.author Lubbe, Martie S. en_US dc.contributor.author Truter, Ilse en_US dc.contributor.author Cottrell, Wayne en_US dc.contributor.author Spirovski, Biljana en_US dc.date.accessioned 2012-02-29T09:49:45Z dc.date.available 2012-02-29T09:49:45Z dc.date.issued 2010 en_US dc.identifier.citation Dranitsaris, G. et al. 2010. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs . Journal of evaluation in clinical practice, 18(2): 343-351. [http://dx.doi.org/10.1111/j.1365-2753.2010.01565.x] en_US dc.identifier.issn 1356-1294 en_US dc.identifier.issn 1365-2753 (Online) en_US dc.identifier.uri http://hdl.handle.net/10394/5950 dc.identifier.uri http://dx.doi.org/10.1111/j.1365-2753.2010.01565.x dc.identifier.uri http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2753.2010.01565.x/abstract dc.description.abstract Rationale, aims and objectives  Value-based pricing has recently been discussed by international bodies as a means to estimate a drug price that is linked to the benefits it offers patients and society. The World Health Organization (WHO) has recommended using three times a country's per capita gross domestic product (GDP) as the threshold for economic value. Using the WHO criteria, pharmacoeconomic modelling was used to illustrate the application of value-based price towards bevacizumab, a relatively new drug that provides a 1.4-month survival benefit to patients with metastatic colorectal cancer (mCRC). Methods  A decision model was developed to simulate outcomes in mCRC patients receiving chemotherapy ± bevacizumab. Clinical data were obtained from randomized trials and costs from Canadian cancer centres. Utility estimates were determined by interviewing 24 oncology nurses and pharmacists. A price per dose of bevacizumab was then estimated using a target threshold of $CAD117 000 per quality adjusted life year gained, which is three times the Canadian per capita GDP. Results For a 1.4-month survival benefit, a price of$CAD830 per dose would be considered cost-effective from the Canadian public health care perspective. If the drug were able to improve patient quality of life or survival from 1.4 to 3 months, the drug price could increase to $CAD1560 and$CAD2180 and still be considered cost-effective. Discussion  The use of the WHO criteria for estimating a value-based price is feasible, but a balance between what patients/governments can afford to pay and the commercial viability of the product in the reference country would be required dc.publisher Wiley en_US dc.subject chemotherapy dc.subject colorectal cancer dc.subject cost analysis dc.subject drug pricing dc.subject value dc.title The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs en_US dc.contributor.researchID 10069712 - Lubbe, Martha Susanna
﻿

## Files in this item

FilesSizeFormatView

There are no files associated with this item.

Theme by